Rare primary liver cancers
- Lesion
Besides the common liver cancers there are rare ones arising from vessels, mixed cell types or lymphocytes.
What it is
A small proportion of primary liver malignancies are neither ordinary hepatocellular carcinoma nor cholangiocarcinoma. Combined hepatocellular-cholangiocarcinoma has both components and shares the risk factors of HCC. Angiosarcoma is an aggressive endothelial tumour linked historically to vinyl chloride, arsenic and thorotrast. Epithelioid hemangioendothelioma is a lower-grade vascular tumour. Lymphomas and other sarcomas can also arise in the liver.
Step by step
- Carcinogens such as vinyl chloride are metabolized in the liver to reactive epoxides.
- These damage DNA of sinusoidal endothelial cells.
- Atypical endothelial cells proliferate along sinusoids, forming irregular vascular channels.
- The tumour bleeds, invades and metastasizes early.
Rare primary malignant tumours of the liver
| Tumour | Cell of origin | Clues | Behaviour |
|---|---|---|---|
| Angiosarcoma | Endothelium | Vinyl chloride, arsenic, thorotrast; hemorrhagic masses | Highly aggressive |
| Epithelioid hemangioendothelioma | Endothelium | Multiple nodules; WWTR1-CAMTA1 fusion | Intermediate, variable |
| Combined hepatocellular-cholangiocarcinoma | Bipotent progenitor or divergent differentiation | Same risks as HCC | Aggressive |
| Primary hepatic lymphoma | B or T lymphocytes | HCV, HIV, immunosuppression | Depends on type |
Markers
- CD31
- CD34
- ERG
- CAMTA1 (nuclear)
- HepPar-1 and keratin 19 (combined tumour)
Test yourself
Think of the answer, then tap the question to see it.
Which three exposures are classically linked to hepatic angiosarcoma?
Vinyl chloride, arsenic and thorotrast.
Which immunostains confirm an endothelial tumour?
CD31, CD34 and ERG.
What gene fusion characterizes epithelioid hemangioendothelioma?
WWTR1-CAMTA1.
Connections
Educational content on the mechanisms of disease; not a diagnostic or treatment guide and no substitute for a health professional's advice. No doses are given.
Sources: Primary Liver Cancer Treatment (PDQ®) - NCI (National Cancer Institute, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.